Shots:

• The company has stopped the patient enrollment early for its P-II (INTRIM 1) trial of tilsotolimod, after interim data delivered positive efficacy results. The trial was conducted by UMC Amsterdam
• The P-II (INTRIM 1) study evaluates tilsotolimod (8mg, ID) vs PBO in patients with pT3-4 cN0M0 melanoma, followed by re-excision & SLN biopsy after 7-10 days
• The interim results showed a lower SLN+ rate (70% vs 40%). This outcome demonstrates earlier results from the same trial which showed immune activation, including elevated frequencies of dendritic cells in early analysis by using flow cytometry of the SLN biopsies. The test seeks to confirm RFS & OS @ 5 & 10yrs. after SLN biopsy

Ref: Globenewswire | Image: Idera